EligibleTrials

Clinical trials recruiting for Exocrine Pancreatic Adenocarcinoma

Fewer than 3 recruiting trials found.

1
Recruiting trials
19
US states with sites
7
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 1

Drugs and treatments being studied

InterventionTrials
Carboplatin1
Cisplatin1
Pembrolizumab1
Sigvotatug Vedotin1

Where trials are recruiting (top US states)

StateRecruiting trials
Alaska1
Arkansas1
California1
Florida1
Illinois1
Indiana1
Kansas1
Massachusetts1
Minnesota1
Nevada1
New York1
Ohio1

Top cities

Anaheim, California 1Anchorage, Alaska 1Babylon, New York 1Bonney Lake, Washington 1Boston, Massachusetts 1Brooklyn, New York 1Calumet City, Illinois 1Chicago, Illinois 1Cleveland, Ohio 1Coon Rapids, Minnesota 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Exocrine Pancreatic Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.

Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Pancreatic cancer 870Ovarian Neoplasms 18Lung cancer 2180Gastroesophageal Junction Adenocarcinoma 11Esophageal Squamous Cell Carcinoma 14Esophageal Adenocarcinoma 15

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Exocrine Pancreatic Adenocarcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.